ERBB2 and breast carcinoma: In cisplatin-resistant HER2-positive breast cancer, NIC combined with cisplatin can inhibit breast cancer cell invasion, the epithelial–mesenchymal transformation, and stem cell differentiation, suggesting that NIC combined with cisplatin may be a new treatment for HER2-positive breast cancer [81].